Azacitidine decreases reactive oxygen species production in peripheral white blood cells:A case report  

作　　者：Hidekazu Hasunuma Naomi Shimizu Hiromitsu Yokota Ichiro Tatsuno 

机构地区：[1]Department of Blood Transfusion,Toho University Medical Center Sakura Hospital,Sakura 2858741,Japan [2]Department of Hematology,Toho University Medical Center Sakura Hospital,Sakura 2858741,Japan [3]Clinical Laboratory Program,Education Development Center,Faculty of Science Toho University,Funabashi 2748510,Japan [4]Center for Diabetes,Metabolism and Endocrinology,Toho University Medical Center Sakura Hospital,Sakura 2858741,Japan

出　　处：《World Journal of Clinical Cases》2020年第22期5657-5662,共6页世界临床病例杂志

摘　　要：BACKGROUND In myelodysplastic syndrome(MDS),oxidative stress is closely related to iron overload and DNA damage.A recent study suggested the possibility that increased oxidative stress causes not only iron overload but also disease progression of MDS with DNA damage.We present a case of MDS with decreased reactive oxygen species(ROS)production in peripheral white blood cells(WBCs)and decreased diacron-reactive oxygen metabolites(d-ROMs)in serum after azacitidine therapy.CASE SUMMARY A 74-year-old man presented to the hematological department with the chief complaint of anemia.His vital signs were within normal limits at admission with a heart rate of 80 bpm and blood pressure of 135/60 mmHg.Laboratory tests indicated pancytopenia,a WBC count of 2190 cells/μL,a hemoglobin level of 6.2 g/dL and a platelet count of 7.4×104/μL.The patient was diagnosed with MDS with fibrosis after a bone marrow examination.This case showed decreased ROS production in WBCs,d-ROMs in serum and Wilms’tumor 1 after azacitidine therapy,after which his hematopoiesis recovered.CONCLUSION Azacitidine therapy can improve hematopoiesis and decrease ROS and d-ROM production.

关 键 词：Myelodysplastic syndrome Reactive oxygen species Diacron-reactive oxygen metabolites FERRITIN AZACITIDINE Case report 

分 类 号：R551.3[医药卫生—血液循环系统疾病]